Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07680868 · ClinicalTrials.gov registry record
Caris Chromoseq Data Collection
A clinical trial, sponsored by Caris Science.
- Recruiting
- Registry status
- 300
- Enrollment target
NCT07680868 is a clinical trial that is actively recruiting participants, run by Caris Science. The registered enrollment target is 300 participants.
The verdict
NCT07680868 is actively recruiting participants, sponsored by Caris Science.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
Study Summary
The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesis of the study is that Caris Chromoseq compares favorably to conventional cytogenetics, FISH, and NGS analysis in terms of risk stratification capabilities, ease of use, and turnaround time.
Interventions
- DIAGNOSTIC_TEST Caris Chromoseq
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07680868
The ClinicalTrials.gov registry entry for NCT07680868 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Caris Science, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Caris Chromoseq is the first listed.
NCT07680868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07680868 about?
NCT07680868 is a clinical study titled "Caris Chromoseq Data Collection". The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesis...
What is the current status of trial NCT07680868?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2026-07. Estimated completion is 2029-07.
What interventions are being tested in trial NCT07680868?
The interventions under investigation include: Caris Chromoseq (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07680868?
This trial is sponsored by Caris Science, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.